Zurich Cantonal Bank’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.19M Sell
55,795
-34,013
-38% -$1.86M 0.01% 889
2026
Q1
$5.07M Buy
89,808
+28,408
+46% +$1.66M 0.01% 646
2025
Q4
$3.65M Sell
61,400
-99,451
-62% -$5.41M 0.01% 713
2025
Q3
$8.71M Sell
160,851
-55,929
-26% -$3.2M 0.02% 489
2025
Q2
$11.9M Buy
216,780
+8,325
+4% +$490K 0.03% 423
2025
Q1
$14.7M Buy
208,455
+9,699
+5% +$653K 0.04% 366
2024
Q4
$13.1M Buy
198,756
+101,794
+105% +$6.82M 0.04% 378
2024
Q3
$6.82M Buy
96,962
+2,588
+3% +$216K 0.02% 507
2024
Q2
$7.77M Buy
94,374
+1,778
+2% +$148K 0.03% 457
2024
Q1
$8.09M Buy
92,596
+14,486
+19% +$1.3M 0.03% 445
2023
Q4
$7.53M Buy
78,110
+42,250
+118% +$3.74M 0.03% 451
2023
Q3
$3.17M Sell
35,860
-556
-2% -$49.5K 0.01% 601
2023
Q2
$3.16M Buy
36,416
+3,171
+10% +$298K 0.01% 608
2023
Q1
$3.23M Sell
33,245
-61
-0.2% -$6.32K 0.02% 591
2022
Q4
$3.45M Sell
33,306
-459
-1% -$43.1K 0.02% 554
2022
Q3
$2.86M Buy
33,765
+4,012
+13% +$357K 0.02% 589
2022
Q2
$2.47M Sell
29,753
-1,412
-5% -$112K 0.01% 634
2022
Q1
$2.4M Buy
31,165
+1,771
+6% +$148K 0.01% 674
2021
Q4
$2.6M Sell
29,394
-14,733
-33% -$1.22M 0.01% 678
2021
Q3
$3.41M Sell
44,127
-1,811
-4% -$143K 0.02% 613
2021
Q2
$3.83M Buy
45,938
+251
+0.5% +$19.9K 0.02% 561
2021
Q1
$3.45M Buy
45,687
+7,346
+19% +$600K 0.02% 568
2020
Q4
$3.36M Buy
38,341
+973
+3% +$77.1K 0.02% 589
2020
Q3
$2.84M Buy
37,368
+8,347
+29% +$845K 0.02% 600
2020
Q2
$3.58M Sell
29,021
-8,492
-23% -$844K 0.03% 470
2020
Q1
$3.17M Buy
37,513
+2,649
+8% +$228K 0.03% 477
2019
Q4
$2.95M Hold
34,864
0.02% 569
2019
Q3
$2.35M Hold
34,864
0.02% 619
2019
Q2
$2.99M Sell
34,864
-8,701
-20% -$744K 0.03% 538
2019
Q1
$3.87M Buy
43,565
+1,470
+3% +$136K 0.03% 463
2018
Q4
$3.58M Buy
42,095
+5,217
+14% +$496K 0.04% 453
2018
Q3
$3.58M Sell
36,878
-645
-2% -$64.4K 0.03% 506
2018
Q2
$3.54M Hold
37,523
0.03% 508
2018
Q1
$3.04M Sell
37,523
-286
-0.8% -$24.5K 0.03% 535
2017
Q4
$3.37M Sell
37,809
-1,696
-4% -$147K 0.03% 504
2017
Q3
$3.68M Sell
39,505
-296
-0.7% -$26.2K 0.03% 469
2017
Q2
$3.62M Sell
39,801
-1,628
-4% -$148K 0.04% 481
2017
Q1
$3.64M Sell
41,429
-1,611
-4% -$143K 0.04% 486
2016
Q4
$3.56M Buy
43,040
+4,042
+10% +$348K 0.04% 483
2016
Q3
$3.61M Buy
38,998
+17,510
+81% +$1.65M 0.04% 472
2016
Q2
$1.67M Hold
21,488
0.02% 579
2016
Q1
$1.77M Hold
21,488
0.02% 574
2015
Q4
$2.25M Buy
21,488
+6,184
+40% +$646K 0.03% 505
2015
Q3
$1.61M Buy
15,304
+1,036
+7% +$138K 0.02% 579
2015
Q2
$1.95M Sell
14,268
-6,578
-32% -$815K 0.03% 534
2015
Q1
$2.6M Buy
20,846
+5,421
+35% +$574K 0.04% 451
2014
Q4
$1.39M Buy
15,425
+5,215
+51% +$434K 0.04% 460
2014
Q3
$737K Sell
10,210
-49,246
-83% -$3.24M 0.02% 593
2014
Q2
$3.7M Buy
59,456
+21,146
+55% +$1.28M 0.11% 229
2014
Q1
$2.61M Sell
38,310
-14,136
-27% -$1.04M 0.08% 281
2013
Q4
$3.69M Sell
52,446
-2,791
-5% -$190K 0.12% 197
2013
Q3
$3.99M Sell
55,237
-30,128
-35% -$2M 0.14% 154
2013
Q2
$4.76M Buy
+85,365
New +$5.32M 0.17% 133

Other funds holding BMRN

Zurich Cantonal Bank's BMRN Position: Q2 2026 in Review

Zurich Cantonal Bank reduced its BioMarin Pharmaceuticals (BMRN) stake by 38% in Q2 2026, selling an estimated $1.86M and leaving 55,795 shares worth $3.19M. The position accounts for 0.01% of the portfolio, ranked #889.

Zurich Cantonal Bank first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.7M in Q1 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Zurich Cantonal Bank held 55,795 shares of BioMarin Pharmaceuticals worth $3.19M as of Q2 2026.
  • Zurich Cantonal Bank sold 34,013 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
  • BioMarin Pharmaceuticals made up 0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #889 holding.
  • Zurich Cantonal Bank first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Zurich Cantonal Bank's BioMarin Pharmaceuticals position peaked at $14.7M in Q1 2025.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.